Dr. Agarwal’s Health Care Ltd. — Q2 and H1 FY27 — November 5, 2026

1. Overall Tone of Management

Optimistic, with some measured caution. Management emphasized accelerating revenue, strong same-store growth, record facility additions, and raised its expansion and capex plans. The confidence is supported by current results, but should be tempered by rising new-center losses, the stated ceiling on premium procedure mix, and limited visibility on doctor attrition and potential regulation.

2. Key Themes from Management Commentary

• Strong growth across existing and newer centers: H1 revenue from operations rose 28.7% year on year; same-store sales growth was 17.7%. Management said mature facilities still have room to grow, while newer centers are ramping up.
• Expansion is shifting further toward surgical facilities: FY27 facility-addition guidance increased to 65, including 55 surgical centers, from 60 facilities and 40 surgical centers. Management cited a strong pipeline and execution, and raised capex guidance.
• Growth is increasingly driven by value as well as volume: H1 domestic growth included 8% volume and 9.5% value contributions. Premiumization contributed about 8% of SSG, while price increases contributed about 1.5%.
• Advanced procedures are gaining traction, but mix has limits: Lenticular procedures grew 41.9% and high-end cataract procedures reached about 30% of cataract surgeries. Management expects high-end cataract share to stabilize around 30–35%, rather than rise indefinitely.
• Geographic expansion is broadening: South remains the largest region; North and West are growing rapidly, and Delhi NCR has reached 15 facilities. Management is adding depth in established markets while building newer clusters.
• Expansion brings near-term costs: H1 EBITDA margin was 28.2%, broadly stable, despite reported losses in the FY26 and FY27 new-center cohorts. Doctor availability and retention remain relevant execution considerations.
• Regulatory uncertainty: Management declined to assess potential controls on markups for lenses or other devices, saying the issue was “premature” and still uncertain.

3. Q&A Analysis

A. Acquisitions, expansion mix and capital spending

Analysts asked: What were the Delhi NCR acquisition’s economics, whether acquisitions will become a larger part of strategy, why surgical centers now make up more of new openings, and how much capex is planned.

Management responded: The two acquired centers generated about ₹13.5 crore of revenue and ₹7.16 crore of business EBITDA over the prior 12 months. The stated purchase price was ₹55 crore: ₹33 crore upfront, with the balance linked to milestones over four years. Greenfield remains the main growth engine; acquisitions are selective, subject to strategic fit and price. Surgical centers are preferred because management sees greater throughput and says typical surgical centers generate ₹75–80 lakh monthly on average.

FY27 capex guidance rose from approximately ₹400 crore to ₹500 crore.

Assessment: The acquisition economics and payment structure were unusually specific and transparent. The strategic answer was clear that acquisitions are complementary, not a replacement for organic growth.

B. Expansion pace, markets and competition

Analysts asked: What has changed on the ground to justify raising facility guidance, how competition affects the outlook, and where the company will expand.

Management responded: Center planning occurs well in advance—projects opening in FY27 were largely identified or contracted earlier. Faster ramp-up in core markets and a strong response in Delhi NCR supported the revised guidance. Management said it would deepen existing southern markets, expand in Mumbai micromarkets, and continue building Delhi NCR. It expects to add 8–12 Delhi NCR centers over the next 9–12 months.

Assessment: Management attributed the guidance revision mainly to prior planning, execution, hiring and better starts, rather than claiming it had suddenly accelerated its operating capability. The answer on competition was indirect: it cited traction and pipeline, without quantifying competitive impact.

C. SSG, volume/value growth and premiumization

Analysts asked: How much growth came from footfall, conversion, pricing and mix; whether premium procedures can keep lifting yields; and whether refractive growth is recovering.

Management responded: For H1 SSG of 17.7%, management attributed about 7% to volume—roughly 6.5% OPD growth and 0.5% conversion—and about 9.5% to value, including around 8% premiumization and 1.5% pricing. It said high-end cataract share is currently about 30% and is likely to remain in a 30–35% range over the next few years, given affordability constraints. Management also said the market is shifting from traditional LASIK to SMILE/lenticular procedures.

Assessment: The explanation distinguishes volume from realization and sets a meaningful limit on the premiumization narrative. The stated expectation of a 30–35% mix ceiling is more restrained than simply extrapolating recent growth.

D. New-center losses and operating costs

Analysts asked: How much the new facilities are losing, and what to assume for employee costs and depreciation.

Management responded: Losses for the FY26 and FY27 cohorts were about ₹42 crore for H1, including approximately ₹20.12 crore for FY26 and ₹18.2 crore for FY27. Management confirmed that employee costs included new facilities and some pre-hired doctors.

Assessment: Losses were quantified, but the call did not provide a clear time-to-breakeven forecast for these cohorts. The rising expansion plan makes this a key execution and margin-monitoring point.

E. Doctor attrition and talent pipeline

Analysts asked: For attrition to be split by seniority and region, and for details on fellowship retention and internal versus external hiring.

Management responded: Overall attrition was described as approximately 14–15%, with senior-doctor attrition below roughly 1–2%. Management did not have exact trainee or fellowship data available and said it would follow up.

Assessment: The senior attrition figure was reassuring, but the response was incomplete on the broader talent pipeline—important given the accelerated center-opening plan.

F. Regulation, pharmacy and cost-of-goods questions

Analysts asked: Whether proposed controls on drug/device markups could affect intraocular lenses, whether a Sun Pharma product issue affected pharmacy sales, and why surgical lens consumption appeared elevated.

Management responded: It said the potential regulation was too uncertain to assess and that it was premature to comment. It said Sun Pharma was not a major supplier and that there was no perceived impact. On lens costs, management referred to overall COGS of approximately 21–21.2% of revenue and said it saw no significant movement.

Assessment: The regulatory answer appropriately acknowledged uncertainty but offered no sensitivity analysis. The lens-cost answer addressed aggregate COGS rather than directly explaining the specific line item raised.

G. Merger status

Analysts asked: Whether regulatory steps remained and when the merger would become effective.

Management responded: The merger was complete; the company said trading would cease on November 17, with the combined entity recorded as Agarwal Healthcare Limited from November 18 and subsidiary shareholders allocated holding-company shares.

Assessment: This was a direct status update, and the timeline is consistent with the earlier expectation of completion around mid-November.

4. Guidance / Outlook

Quantitative guidance

• FY27 network additions: 65 facilities, including 55 surgical centers; prior guidance was 60 facilities, including 40 surgical centers.
• H2 FY27 additions: 26 facilities, including 21 surgical facilities.
• FY27 capex: Increased from approximately ₹400 crore to ₹500 crore.
• Premium cataract mix: Management expects high-end cataract procedures to stabilize around 30–35% of cataract volume over the next few years.
• Delhi NCR: Management expects to add 8–12 centers over the next 9–12 months.

Qualitative signals

• Management expects growth momentum to continue, supported by mature-center growth, new geographies and advanced procedures.
• It cited strong patient traction and early ramp-up in newer facilities, while acknowledging that recently opened cohorts are loss-making.
• No explicit full-year FY27 revenue or EBITDA-margin target was provided. Margins were described as broadly stable despite expansion costs.

5. Standout Statements

• “Our same-store sales growth has been stellar this year.”
• “We are now targeting an addition of 65 new facilities during the year, which includes 55 new surgical facilities.”
• “We do not expect this mix of high-end procedures to go to 50% or 60%. It will stabilize at 30-35% at least for the next few years.”
• “The growth engine for the company continues to remain organic expansion.”
• On regulation: “It would be premature for us to comment right now” on whether proposed markup controls pose a risk.

6. Red Flags / Positive Signals

Red flags
– H1 new-center losses were about ₹42 crore, while the company raised its annual opening target and capex.
– Management lacked detailed attrition and fellowship-retention data during the call.
– Potential controls on device markups remain unquantified.
– The transcript contains some internal inconsistencies in facility counts and classifications. Treat detailed opening arithmetic cautiously and verify against company filings.

Positive signals
– Strong 17.7% H1 SSG and 28.7% H1 revenue growth.
– EBITDA margin remained broadly stable despite expansion costs.
– Expansion guidance was raised after 39 facility additions in H1.
– Senior-doctor attrition was stated to be low, at roughly 1–2%.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q3 FY26
– Dominant tone: Optimistic
– Major themes this quarter:
– Double-digit revenue and EBITDA growth, with expanding PAT margin.
– Greenfield expansion and faster ramp-up in newer facilities.
– Technology, premiumization and complex procedures.
– Refractive softness, weather/festival effects and rising employee costs.
– Tone shift vs previous quarter: N/A (baseline)
– What changed: N/A (baseline)

Q4 FY26
– Dominant tone: Optimistic
– Major themes this quarter:
– FY26 revenue crossed ₹2,000 crore; full-year EBITDA margin improved.
– FY27 expansion plan of 60 facilities, including 40 surgical centers.
– Growth expected to continue at a similar pace; EBITDA margins expected to stay stable.
– Delhi NCR build-out and planned Chennai facility investment.
– Tone shift vs previous quarter: No Change
– What changed:
– Full-year delivery strengthened the confidence expressed in Q3.
– Management set a concrete FY27 facility and capex plan, while acknowledging start-up losses and compliance/property constraints.

Q1 FY27
– Dominant tone: Optimistic
– Major themes this quarter:
– Record quarterly surgical openings and strong revenue growth.
– High SSG and increasing advanced-procedure volumes.
– Delhi NCR expansion and a pipeline of signed LOIs.
– Stable margins despite new-center costs.
– Tone shift vs previous quarter: More Optimistic
– What changed:
– Management emphasized record execution and strong patient traction.
– FY27 guidance remained at 60 facilities/40 surgical centers; capex was guided at ₹380–400 crore.
– Management was cautious on how high realization growth could persist, but positive on the direction of premiumization.

Q2 FY27
– Dominant tone: Optimistic
– Major themes this quarter:
– Accelerating revenue, strong SSG and record H1 expansion.
– More surgical-center openings and higher capex.
– Advanced procedures, especially lenticular surgery, supporting value growth.
– New-center losses and unresolved regulatory uncertainty.
– Tone shift vs previous quarter: More Optimistic
– What changed:
– FY27 guidance increased to 65 facilities/55 surgical centers and ₹500 crore capex.
– Management cited strong execution and market traction, while clarifying that high-end cataract mix has a practical 30–35% ceiling.
– Regulatory uncertainty and incomplete talent data were more visible in Q&A.

Trajectory Summary: Management’s tone has remained positive across all four calls, with confidence rising as growth and center openings accelerated. The main change is a larger commitment to expansion and investment in Q2 FY27; the key counterweight is that new-center losses are increasing in absolute terms and the company has not provided a quantified full-year margin outlook.

b. Tracking Past Commitments vs Outcomes

• FY26 expansion guidance: Management targeted roughly 55–60 additions; Q3 reported 38 additions through nine months and Q4 reported 19 additions in the quarter, implying about 57 gross additions. ✅ Delivered
• FY27 expansion plan: Q4 set guidance at 60 facilities/40 surgical centers; Q1 maintained that plan. Q2 raised it to 65/55 after 39 H1 additions. ✅ Progressing; guidance raised
• FY27 capex: Q4 indicated ₹380–400 crore, and Q1 referenced approximately ₹400 crore; Q2 raised this to ₹500 crore. ⏳ Revised upward, not yet an outcome
• Chennai CMS facility: Q4 targeted an October 1, 2026 launch, subject to approvals. The Q2 call did not update its status. Not mentioned again; delivery unverified
• Merger: Q4 expected completion around the end of the year, and Q1 expected mid-November. Q2 said it was complete, with trading to cease November 17. ✅ Delivered / timeline advanced
• Ethiopia market entry: Q3 described a feasibility study and said capex estimates would follow. Q4 through Q2 did not revisit it. ❌ Dropped from current discussion / no update

c. Narrative Shifts

• Expansion is now more explicitly surgical-center-led: the FY27 plan increased from 40 to 55 surgical openings.
• Delhi NCR has shifted from a new-market experiment to a substantial cluster, with 15 centers and further additions planned.
• Premiumization remains a growth lever, but management now explicitly says high-end cataract mix is unlikely to exceed 30–35% in the near term.
• Regulation around device markups is a more explicit potential risk than in the earlier calls.
• Ethiopia, previously discussed as a growth opportunity, was absent from the current call.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management’s core story—organic expansion, double-digit mature-center growth, stable margins and technology-led premiumization—has been broadly consistent. The company has updated facility and capex guidance in response to execution, and it quantified new-center losses. However, attrition and fellowship questions were not answered with complete data, the Chennai facility was not updated against its prior timeline, and the current transcript’s facility arithmetic is not fully consistent.

e. Evolution of Key Themes

• Demand / SSG — Improving: Mature-center SSG moved from about 14% for FY26 to 16.3% in Q1 and 17.7% for H1 FY27.
• Expansion — Improving / accelerating: Facility guidance rose from 60 to 65, and surgical openings from 40 to 55.
• Margins — Stable: EBITDA margins were 28.4% in Q3 FY26, 28.9% for FY26, 28.5% in Q1 FY27 and 28.2% for H1 FY27. New-center costs are absorbing some operating leverage.
• Premiumization — Improving, but bounded: High-end cataract share rose from 26.3% in FY26 to about 30% in H1 FY27; management expects the mix to settle around 30–35%.
• Talent — Watch item: Senior-doctor attrition was described as low, but total attrition remains around 14–15%, and detailed retention data were not supplied.
• Regulation — Deteriorating visibility: Potential pricing restrictions on lenses/devices have surfaced as a risk, but management considers the outcome too uncertain to assess.

f. Additional Insights (Cross-Period Intelligence)

• Growth is increasingly being supported by realization and premiumization, not only patient volumes. Management’s own H1 SSG split attributes about 8 percentage points to premiumization, but its stated 30–35% mix ceiling makes continued realization growth dependent on broader volume, conversion and price contributions.
• The expansion upgrade is not presented as a sudden change in operating capacity: management says sites are planned 12–18 months ahead. This supports execution credibility, but also means future openings depend on the quality of an already-built pipeline.
• Margin stability masks growing investment: new-center cohort losses reached about ₹42 crore in H1 while capex guidance rose to ₹500 crore. Stable consolidated margins therefore do not mean expansion costs are falling.